NewLimit Closes $435M Series C at $3.1B Valuation for Age-Reprogramming Medicine
NewLimit, the longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, closed a $435 million Series C funding round on June 2 to advance its first age-reprogramming medicine into human clinical trials. The round, led by Founders Fund, values the company at $3.1 billion—more than
CryptoFrontier·06-03 18:52
